BioCentury
ARTICLE | Finance

Doubling up

Endocyte tops up after stock jumps on Vynfinit CHMP nod, NSCLC data

March 31, 2014 7:00 AM UTC

Endocyte Inc. (NASDAQ:ECYT) wasted no time padding its coffers after its stock almost doubled on a nod from EMA's CHMP for Vynfinit vintafolide and data in non-small cell lung cancer (NSCLC).

Endocyte raised $94.5 million last week through the sale of 4.5 million shares at $21 in a follow-on underwritten by Credit Suisse; Citigroup; Cowen; RBC Capital Markets; Baird; Wedbush PacGrow; and Roth Capital Partners...